On November 29, 2018, American Committee supporters from across the U.S. tuned in for new CEO Dave Doneson’s first video conference, “Weizmann Science: Why Basic Research Matters and Merits Our Support.” In conversation with Bonnie Diamond, Senior Vice President of Donor Relations & National Programs, Mr. Doneson illustrated the value of basic science by sharing the stories of three transformative breakthroughs.

The launch of penicillin in the 1940s, beginning the era of antibiotics, is one of the greatest advances in medicine. Mr. Doneson told the story of the accidental event that led to the discovery of a mold that killed bacteria.

He then shared how radio astronomers adapted their discovery that filtered cosmic noise to improve Wi-Fi networks and launch the mobile technology boom.

Lastly, he recounted how Weizmann scientists developed synthetic molecules believing they would induce symptoms of multiple sclerosis, but instead, they ended up blocking the disease. This surprising finding led to the development of the frontline MS treatment, Copaxone®.

Driven by their own curiosity and their desire to address some of the world’s greatest challenges, Weizmann scientists seek to improve the quality of life of every person on the planet.

To view the recording of the November 29, 2018 video conference, we invite you to play it below.

Call Archives:

The April 11, 2018 call highlighting a universal flu vaccine, a molecule that may “unlock” renewal of the heart following an attack, and an approach to stabilizing protein structures which could help prevent malaria.

The October 10, 2017 call featured recent advances in cancer treatment and a glimpse into the world of intelligent machines.

The inaugural February 28, 2017 call focused on Alzheimer’s research and Weizmann’s Bench-to-Bedside Project.

CEO Donor Video Conference Highlights Why Basic Research Matters

• TAGS: Community, Philanthropy, Leadership, Technology, Medicine, Multiple sclerosis

On November 29, 2018, American Committee supporters from across the U.S. tuned in for new CEO Dave Doneson’s first video conference, “Weizmann Science: Why Basic Research Matters and Merits Our Support.” In conversation with Bonnie Diamond, Senior Vice President of Donor Relations & National Programs, Mr. Doneson illustrated the value of basic science by sharing the stories of three transformative breakthroughs.

The launch of penicillin in the 1940s, beginning the era of antibiotics, is one of the greatest advances in medicine. Mr. Doneson told the story of the accidental event that led to the discovery of a mold that killed bacteria.

He then shared how radio astronomers adapted their discovery that filtered cosmic noise to improve Wi-Fi networks and launch the mobile technology boom.

Lastly, he recounted how Weizmann scientists developed synthetic molecules believing they would induce symptoms of multiple sclerosis, but instead, they ended up blocking the disease. This surprising finding led to the development of the frontline MS treatment, Copaxone®.

Driven by their own curiosity and their desire to address some of the world’s greatest challenges, Weizmann scientists seek to improve the quality of life of every person on the planet.

To view the recording of the November 29, 2018 video conference, we invite you to play it below.

Call Archives:

The April 11, 2018 call highlighting a universal flu vaccine, a molecule that may “unlock” renewal of the heart following an attack, and an approach to stabilizing protein structures which could help prevent malaria.

The October 10, 2017 call featured recent advances in cancer treatment and a glimpse into the world of intelligent machines.

The inaugural February 28, 2017 call focused on Alzheimer’s research and Weizmann’s Bench-to-Bedside Project.